**4. Organoid commercialization**

Organoids are 3D microtissue replicators that have been successfully employed for various applications, including disease modeling, drug screening, pathogenesis research, stem cell research, and tumor immunology. Organoids are as diverse as the tissues and organs of the human body and have immense economic potential [21, 22]. They have the potential to pave the path for personalized treatment and precision medicine (**Figure 1**). PDOs have been utilized in clinical trials to predict patient responses to therapy regimens and perhaps enhance cancer treatment results. Recent advances in stem cell research and genomic technology have resulted in ground-breaking breakthroughs in organoid bioengineering, large-scale production, biobanking, and commercialization [6]. This section of the book reviews the concept of organoid biobanking, the firms engaged, the commercialization process, and ethical issues. Additionally, this book discusses possible barriers to clinical translation of organoids and suggests future research avenues for therapeutic translation and cancer treatment. This collection of chapters is intended for a wide readership and will serve as an indispensable resource for fundamental biologists, translational scientists, and clinicians.
